Karen Knudsen: Access to clinical trials is access to the most advanced cancer care

Karen Knudsen shared the following post by Kent Thoelke, CEO of Paradigm, on LinkedIn, adding the following:

“Congratulations, Kent Thoelke and the entire Paradigm team. Access to clinical trials IS access to the most advanced cancer care. We are proud at American Cancer Society to work with you and fully believe in the mission!”

Quoting Kent Thoelke’s post:

“I’m in Tel Aviv today announcing a groundbreaking partnership with Sheba Medical Center, Tel Hashomer and ARC Innovation and Paradigm Health. It was an honor to be part of this announcement in person today with Eyal Zimlichman, MD, CITO Sheba Medical Center/Director ARC Innovation, Stephen Klasko, Board Member, Paradigm Health and Jonathan Hirsch, Chief Strategy Officer, Paradigm Health. Today at a signing ceremony, we highlighted Sheba’s ongoing leadership in clinical trials and the role Paradigm Health will play in supporting the scaling of clinical trials throughout Israel, and the development of a global clinical trials network with Sheba and ARC.

Sheba Medical Center is Israel’s largest hospital and a well-established leader globally in clinical trials. Through the deployment of the Paradigm Health platform, we will help extend Sheba’s reach, efficiency, and capabilities across Sheba and their affiliated clinics. We will be collaborating to streamline trial operations, including feasibility assessments, patient screening, recruitment, and data collection.

Sheba is widely used as a location for biopharma clinical trials, and our work together will expand their capacity by lowering the administrative burden of trials. That means more patients will have access to clinical trials, innovative treatments, and providers will be able to spend more time focusing on patient care rather than paperwork.

We’re grateful for the trust of ARC Innovation and Sheba Medical Center, and honored to help serve their patients. From Israel to Japan to North Dakota and beyond, we’re building a new, end-to-end clinical trials platform and changing the paradigm for patient care and clinical trial access globally.”

Read further.
Source: Karen Knudsen/LinkedIn and Kent Thoelke/LinkedIn

Karen Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR). She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.